Galectin Therapeutics to Present Clinical Data at The Liver Meeting® 2017 Demonstrating the Ability of Non-Invasive Test to Identify Clinically Significant Portal Hypertension in Patients with Compensated NASH Cirrhosis
October 20, 2017 08:30 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Oct. 20, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that Dr. Raj...
InSphero to Present Novel 3D Human Liver Fibrosis Model at Annual Liver Meeting® in Washington, DC
October 18, 2017 08:00 ET
|
InSphero AG
Schlieren, Switzerland, Oct. 18, 2017 (GLOBE NEWSWIRE) -- InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, will present data...
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...
Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
September 12, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Clarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business Update
August 18, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, is issuing this press release to...
Galectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business Update
May 15, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., May 15, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease
May 03, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., May 03, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
April 18, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update
March 28, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 28, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for...
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
March 23, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...